SG11201808751SA - T cell receptors - Google Patents
T cell receptorsInfo
- Publication number
- SG11201808751SA SG11201808751SA SG11201808751SA SG11201808751SA SG11201808751SA SG 11201808751S A SG11201808751S A SG 11201808751SA SG 11201808751S A SG11201808751S A SG 11201808751SA SG 11201808751S A SG11201808751S A SG 11201808751SA SG 11201808751S A SG11201808751S A SG 11201808751SA
- Authority
- SG
- Singapore
- Prior art keywords
- tcrs
- international
- park
- abingdon
- pct
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 9
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108010012015 GVYDGREHTV Proteins 0.000 abstract 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 October 2017 (12.10.2017) WIPO I PCT (10) International Publication Number WO 2017/174824 Al 11111111111111011101111111111101011111011101011101111111010101111111111111110111111 (51) International Patent Classification: C07K 14/725 (2006.01) CO7K 14/47 (2006.01) (21) International Application Number: PCT/EP2017/058580 (22) International Filing Date: 10 April 2017 (10.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1606177.2 8 April 2016 (08.04.2016) GB (71) Applicant: ADAPTIMMUNE LIMITED [GB/GB]; 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). (72) Inventors: TRIBBLE, Nicholas; c/o Adaptimmune Lim- ited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). LAWRANCE, William; c/o Adaptim- mune Limited, 101 Park Drive, Milton Park, Abingdon Ox- fordshire OX14 4RY (GB). BAGG, Eleanor; c/o Adaptim- mune Limited, 101 Park Drive, Milton Park, Abingdon Ox- fordshire OX14 4RY (GB). (74) Agent: BIRTLE, Zoe; 30 Carlton Crescent, Southampton, Hampshire S015 2EW (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 1717 / 48 24 Al (54) Title: T CELL RECEPTORS (57) : The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGRE- HTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring ex - pression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606177 | 2016-04-08 | ||
| PCT/EP2017/058580 WO2017174824A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808751SA true SG11201808751SA (en) | 2018-11-29 |
Family
ID=58701592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808751SA SG11201808751SA (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11286289B2 (en) |
| EP (2) | EP3440106B1 (en) |
| JP (2) | JP7240176B2 (en) |
| KR (2) | KR102523449B1 (en) |
| CN (2) | CN109476725B (en) |
| AU (2) | AU2017248122B2 (en) |
| BR (1) | BR112018070625A2 (en) |
| CA (1) | CA3020058A1 (en) |
| CY (1) | CY1124664T1 (en) |
| DK (1) | DK3440106T3 (en) |
| ES (1) | ES2891321T3 (en) |
| HR (1) | HRP20211493T1 (en) |
| HU (1) | HUE056433T2 (en) |
| IL (1) | IL262128A (en) |
| LT (1) | LT3440106T (en) |
| MX (2) | MX2018012269A (en) |
| PL (1) | PL3440106T3 (en) |
| PT (1) | PT3440106T (en) |
| RS (1) | RS62623B1 (en) |
| RU (1) | RU2018138838A (en) |
| SG (1) | SG11201808751SA (en) |
| SI (1) | SI3440106T1 (en) |
| WO (1) | WO2017174824A1 (en) |
| ZA (1) | ZA201806866B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211327T1 (en) | 2014-12-23 | 2022-01-21 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| KR20190065189A (en) * | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T cell receptor |
| CN117603339A (en) * | 2016-04-08 | 2024-02-27 | 艾达普特免疫有限公司 | T cell receptor |
| MX2018012269A (en) | 2016-04-08 | 2019-05-30 | Adaptimmune Ltd | T cell receptors. |
| KR20200063215A (en) | 2017-10-06 | 2020-06-04 | 오슬로 유니버시테시케후스 에이치에프 | Chimeric antigen receptor |
| CN109777778B (en) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | Genetically modified gamma delta T cells |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN114585646A (en) * | 2019-06-18 | 2022-06-03 | 里珍纳龙药品有限公司 | MAGE-A4T cell receptor and methods of use thereof |
| CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20230000913A1 (en) | 2019-08-13 | 2023-01-05 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| EP4076666A1 (en) | 2019-12-18 | 2022-10-26 | F. Hoffmann-La Roche AG | Antibodies binding to hla-a2/mage-a4 |
| CN117964757A (en) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | Antibodies and fusion proteins that bind CCR8 and uses thereof |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| KR20230169944A (en) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | MAGE-A4 peptide-MHC antigen binding protein |
| TW202313094A (en) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | Methods of using flt3l-fc fusion proteins |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| WO2023076863A2 (en) * | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use |
| TW202330504A (en) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| TW202346277A (en) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros zinc finger family degraders and uses thereof |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| TW202400138A (en) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| AU2023241307A1 (en) * | 2022-10-05 | 2024-05-02 | Tscan Therapeutics Inc | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
| AU2023241306A1 (en) * | 2022-10-05 | 2024-05-02 | Tscan Therapeutics Inc | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0869943A1 (en) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| RU2355703C2 (en) | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Single-strand recombinant t-cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US8003770B2 (en) * | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| US9586997B2 (en) | 2010-09-20 | 2017-03-07 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific T cell receptors and T cell epitopes |
| JP2015502915A (en) * | 2011-10-14 | 2015-01-29 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Antibody against CD1d |
| KR20190065189A (en) | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T cell receptor |
| CN117603339A (en) | 2016-04-08 | 2024-02-27 | 艾达普特免疫有限公司 | T cell receptor |
| MX2018012269A (en) | 2016-04-08 | 2019-05-30 | Adaptimmune Ltd | T cell receptors. |
-
2017
- 2017-04-10 MX MX2018012269A patent/MX2018012269A/en unknown
- 2017-04-10 BR BR112018070625A patent/BR112018070625A2/en unknown
- 2017-04-10 RU RU2018138838A patent/RU2018138838A/en unknown
- 2017-04-10 EP EP17723016.6A patent/EP3440106B1/en active Active
- 2017-04-10 HU HUE17723016A patent/HUE056433T2/en unknown
- 2017-04-10 KR KR1020187032168A patent/KR102523449B1/en active IP Right Grant
- 2017-04-10 PT PT177230166T patent/PT3440106T/en unknown
- 2017-04-10 SG SG11201808751SA patent/SG11201808751SA/en unknown
- 2017-04-10 EP EP21193647.1A patent/EP3988565A1/en active Pending
- 2017-04-10 CN CN201780031710.2A patent/CN109476725B/en active Active
- 2017-04-10 CN CN202310190624.3A patent/CN116217703A/en active Pending
- 2017-04-10 LT LTEPPCT/EP2017/058580T patent/LT3440106T/en unknown
- 2017-04-10 AU AU2017248122A patent/AU2017248122B2/en active Active
- 2017-04-10 WO PCT/EP2017/058580 patent/WO2017174824A1/en active Application Filing
- 2017-04-10 PL PL17723016T patent/PL3440106T3/en unknown
- 2017-04-10 SI SI201730915T patent/SI3440106T1/en unknown
- 2017-04-10 ES ES17723016T patent/ES2891321T3/en active Active
- 2017-04-10 CA CA3020058A patent/CA3020058A1/en active Pending
- 2017-04-10 KR KR1020237007661A patent/KR20230044016A/en not_active Application Discontinuation
- 2017-04-10 JP JP2018552872A patent/JP7240176B2/en active Active
- 2017-04-10 HR HRP20211493TT patent/HRP20211493T1/en unknown
- 2017-04-10 RS RS20211132A patent/RS62623B1/en unknown
- 2017-04-10 DK DK17723016.6T patent/DK3440106T3/en active
-
2018
- 2018-10-04 IL IL262128A patent/IL262128A/en unknown
- 2018-10-05 MX MX2022011309A patent/MX2022011309A/en unknown
- 2018-10-08 US US16/154,192 patent/US11286289B2/en active Active
- 2018-10-15 ZA ZA2018/06866A patent/ZA201806866B/en unknown
-
2021
- 2021-10-05 CY CY20211100860T patent/CY1124664T1/en unknown
- 2021-10-14 US US17/501,122 patent/US11725040B2/en active Active
-
2022
- 2022-08-17 US US17/820,529 patent/US11572400B1/en active Active
- 2022-10-20 AU AU2022256177A patent/AU2022256177A1/en active Pending
-
2023
- 2023-03-03 JP JP2023032695A patent/JP2023081949A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808751SA (en) | T cell receptors | |
| SG11201808750PA (en) | T cell receptors | |
| SG11201808709VA (en) | T cell receptors | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |